2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapyBedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, Utpatel C, Cirillo D, Rodrigues C, Nilgiriwala K, Fowler P, Merker M, Niemann S, Consortium C, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Dreyer V, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grandjean L, Grazian C, Groenheit R, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Khot R, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Mansjö M, Matias D, Meintjes G, de Freitas Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Musser K, Ngcamu D, Hoang N, Niemann S, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Rodger G, Rodrigues C, Rodwell T, Roohi E, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker S, Warren R, Werngren J, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Yu X, Yang Y, Zhao Y, Yao S, Zhu B. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. The Lancet Microbe 2023, 4: e358-e368. PMID: 37003285, PMCID: PMC10156607, DOI: 10.1016/s2666-5247(23)00002-2.Peer-Reviewed Original ResearchConceptsMutation catalogueIn silico data analysisBedaquiline resistanceClofazimine resistanceResistance mechanismsProtein modelsClinical Mycobacterium tuberculosis complex isolatesImpaired DNA bindingClinically resistant strainsMinimum inhibitory concentrationVariants in vitroPacBio sequencingGenome sequenceGenomic rearrangementsGenomic variantsIn vitroExperimental evolutionGenotype dataTranscriptional repressorDrug resistance mechanismsClinical isolatesPhenotypic dataResistance determinantsDNA bindingProtein dimerisation
2020
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. The Journal Of Infectious Diseases 2020, 222: 1027-1036. PMID: 32310272, DOI: 10.1093/infdis/jiaa195.Peer-Reviewed Original ResearchConceptsB. microti parasitesMicroti infectionHigh-grade parasitemiaDrug-resistant tuberculosisB. microtiBabesia microti infectionAdditional preclinical studiesB. microti infectionImmunocompromised hostB. microti DNAPolymerase chain reactionPreclinical studiesIncidence of babesiosisPromising drugRadical cureMinimal doseClofazimineDay 10Blood smearsBabesia microtiNovel drugsParasitemiaChain reactionMicroscopic examinationAntimicrobial agents
2016
Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo
Chuang YM, Dutta NK, Hung CF, Wu TC, Rubin H, Karakousis PC. Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo. Antimicrobial Agents And Chemotherapy 2016, 60: 6460-6470. PMID: 27527086, PMCID: PMC5075050, DOI: 10.1128/aac.01139-16.Peer-Reviewed Original ResearchMeSH KeywordsAcid Anhydride HydrolasesAnimalsAntitubercular AgentsBiofilmsCitric Acid CycleClofazimineDisease Models, AnimalDrug Resistance, BacterialGene ExpressionGlycerophosphatesIsoenzymesIsoniazidMeropenemMiceMycobacterium tuberculosisNaphthoquinonesPhosphotransferases (Phosphate Group Acceptor)PolyphosphatesThienamycinsTuberculosis VaccinesTuberculosis, Multidrug-ResistantVaccines, DNAXyloseConceptsM. tuberculosisVaccine-induced immunityGlobal health threatActivity of isoniazidMedical nonadherenceChronic tuberculosisProlonged therapyDNA vaccineAntibiotic treatmentMycobacterium tuberculosis metabolismReal-time PCRMurine modelM. tuberculosis metabolismAntibiotic toleranceLow intracellular levelsProtective activityAntibiotic sensitivityDrug resistanceTuberculosisLiquid chromatography-tandem mass spectrometryMycobacterium tuberculosisHealth threatKey regulatory moleculesChromatography-tandem mass spectrometryEnhanced susceptibility
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply